Merck Sharp & Dohme Corp Patent Portfolio Statistics

Merck Sharp & Dohme Corp.

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Merck Sharp & Dohme Corp. look like?

Total Applications: 4,299
Granted Patents: 3,192
Grant Index 78.68 %
Abandoned/Rejected Applications: 865 (21.32%)
In-Process Applications: 229
Average Grant Time: 2.55 Years
Average Office Actions: 1.38

Which Technology Area Merck Sharp & Dohme Corp. is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1624 Organic Chemistry 699
1625 Organic Chemistry 647
1626 Organic Chemistry 488
1646 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 161
1622 Organic Chemistry 124

How many patents are Merck Sharp & Dohme Corp. filing every year?

Year Total Applications
2022 0*
2021 107*
2020 104
2019 121
2018 158

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Merck Sharp & Dohme Corp. in USPTO?

Publication number:
Application number: 17/606,154

Abstract:
None

Publication date:
Applicant: Merck Sharp & Dohme Corp.
Inventors: Brian Campbell T


Publication number: US20220023285A1
Application number: 17/502,962

Abstract:
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I):wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.

Publication date: 2022-01-27
Applicant: Merck Sharp & Dohme Corp.
Inventors: Hori Yusaku


Publication number: US20220016031A1
Application number: 17/489,296

Abstract:
A process for preparing and isolating pharmaceutical active ingredient particles having a particle size of between about 0.1 and 30 microns, wherein a slurry comprising the active ingredient and one or more pharmaceutically acceptable excipients is fed into a thin film evaporator under suitable conditions for less than 10 minutes sufficient to generate solid matrix particles comprising active ingredient and one or more excipients, wherein the particles have less than 5% residual solvent.

Publication date: 2022-01-20
Applicant: Merck Sharp & Dohme Corp.
Inventors: David J Lamberto


How are Merck Sharp & Dohme Corp.’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/606,154 Spiropiperidine Allosteric Modulators Of Nicotinic Acetylcholine Receptors Sent to Classification contractor
17/502,962 Combination Of A Pd-1 Antagonist And A Vegfr/Fgfr/Ret Tyrosine Kinase Inhibitor For Treating Cancer OPAP Central, Docket
17/489,296 Process For Preparing Pharmaceutical Compositions OPAP Central, Docket